Skip to content

A Clinical study to determine the effect of intravenous dexmedetomidine in patients given spinal anesthesia

EFFECTS OF INTRAVENOUS DEXMEDETOMIDINE ON THE DURATION OF SUBARACHNOID BLOCK WITH HYPERBARIC BUPIVACAINE

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/05/004616
Enrollment
90
Registered
2014-05-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASA 1&2

Interventions

Intervention1: intravenous dexmedetomidine: intravenous DEXMEDETOMIDINE 0.5 ug/kg/hr will be given as a bolus dose over 15min(group b) intravenous DEXMEDETOMIDINE 0.5ug/kg/hr for 15 min, followed by 0

Sponsors

Dr Anil Thomas
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: all patients Who give informed valid consent Patients scheduled for lower abdominal, urological, gynaecological and orthopaedic surgeries under spinal anaesthesia

Exclusion criteria

Exclusion criteria: Any contra-indication to sub arachnoid block like hypotension, coagulation defects, spine abnormalities etc. Body weight >120 kg and height Patients with labile hypertension, heart block, arrhythmias. Patients on calcium channel blockers, adrenergic receptor blockers, ACE inhibitors α- adrenergic agonists. Allergic to the drug. Pregnancy

Design outcomes

Primary

MeasureTime frame
To compare the duration of Sensory and Motor block with the addition of intravenous dexmedetomidine to intrathecal hyperbaric BupivacaineTimepoint: 24HOURS

Secondary

MeasureTime frame
1. To study the duration of analgesia and the level of sedation. 2. To study the hemodynamic effect. 3. To study the occurrence of side effects Timepoint: ONE MONTH

Countries

India

Contacts

Public ContactDrM V S SATYAPRAKASH

J.I.P.M.E.R

munaganuri1975@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026